Gland Pharma launches cancer drug Bortezomib in US
Hyderabad: Gland Pharma Limited, a generic injectable focused pharmaceutical company, through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market.
It is the bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc.
Bortezomib for Injection is used to treat certain types of cancer such as multiple myeloma (cancer of plasma cells) and mantle cell lymphoma (cancer of lymph nodes).
Velcade has a market size of USD 1,172 million for the twelve months ending March 2022, according to IQVIA. Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (USFDA).
Gland Pharma is manufacturing and supplying this product to its partner for the US market.
Read also: Gland Pharma bags USFDA nod for Cangrelor for Injection
Medical Dialogues team had earlier reported that Aurobindo Pharma Limited's wholly owned subsidiary, Eugia Pharma Specialties Limited and Zydus Lifesciences had received a final approval from the US Food & Drug Administration (USFDA) to market Bortezomib for injection, 3.5 mg.
Read also: Aurobindo Pharma arm bags USFDA nod for cancer drug Bortezomib
Gland Pharma, a generic injectable focused pharmaceutical company was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions. The company has global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.
Read also: Zydus Lifesciences bags USFDA nod for Bortezomib for Injection to treat cancer
